1. Introduction {#s0005}
===============

Since the late of December 2019, a newly recognized novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread rapidly in China and around the world [@b0005]. According to the report of World Health Organization on May 18, 2020, the total number of confirmed cases has risen sharply to 4,618,821 in more than 110 countries, with 311,847 (6.8%) deceased cases [@b0010]. The population is generally susceptible to SARS-CoV-2 infection. However, several epidemiological studies had described that older adults and those with certain underlying diseases are more vulnerable to the disease, with diabetes mellitus (DM) being one of the most frequent comorbidities [@b0005], [@b0015], [@b0020].

It has been estimated that 463 million adults are living with diabetes worldwide [@b0025], and those individuals are at a higher risk of infection and may have worse outcomes than the population without diabetes once infected [@b0030], [@b0035]. Previous studies demonstrated that diabetes was an independent risk factor for mortality in patients with Severe Acute Respiratory Syndrome coronavirus (SARS-CoV), Pandemic Influenza A (H1N1) and Middle East Respiratory Syndrome coronavirus (MERS-CoV) [@b0040], [@b0045], [@b0050]. Angiotensin-converting enzyme 2 (ACE2) is a functional receptor for SARS-CoV that is expressed in pancreatic islets, among others, which can aggravate the diabetes progression [@b0055]. Notably, SARS-CoV-2 can also bind to the target cells through ACE2 and the affinity is 10--20 times higher than SARS-CoV [@b0060]. Therefore, COVID-19 patients with diabetes might have higher disease severity and poor prognosis. However, the available information regarding COVID-19 patients with diabetes is inadequate at present.

Hence, this study aimed to analyze the detailed clinical characteristics, laboratory findings and HRCT features and to explore the risk factors for in-hospital death and complications of COVID-19 patients with diabetes.

2. Materials and methods {#s0010}
========================

2.1. Patients {#s0015}
-------------

This was a retrospective cohort study carried out at two hospitals in Hubei province, China (Wuhan Union hospital of Tongji Medical College and Jinyintan Hospital). All patients with pre-existing diabetes who were diagnosed with SARS-CoV-2 pneumonia according to WHO interim guidance [@b0065], and those who died or were discharged from hospital between Dec 31, 2019, and Apr 5, 2020, were included in this study. The study was approved by the institutional review boards of the two hospitals. Informed consent was waived for this retrospective study.

2.2. Data collection {#s0020}
--------------------

All admission data were obtained from patients' electronic medical records and were reviewed by two physicians (Jin Gu and Yue Cui). Information extracted included demographic data, exposure history, comorbidities, symptoms, treatments, in-hospital complications, outcomes, laboratory results and chest CT images. Based on the fasting blood glucose (FBG) levels on admission, two groups of patients were designated: group 1 (with FBG ≤ 11 mmol/L) and group 2 (with FBG \> 11 mmol/L).

2.3. Outcomes and definitions {#s0025}
-----------------------------

The primary outcomes included an intensive care unit (ICU) entry and in-hospital death. The secondary outcomes were any in-hospital complications, including SARS-CoV-2-related ARDS, acute cardiac injury, acute kidney injury and secondary infection. ARDS was diagnosed based on the WHO guidance for COVID-19 [@b0065]. Acute cardiac injury was identified if the serum ﻿high-sensitivity cardiac troponin I level was above the upper limit of the 99th percentile reference [@b0070]. Acute kidney injury was diagnosed according to the clinical practice guidelines of KDIGO [@b0075]. Secondary infection was identified if the patient had a positive culture of a new pathogen obtained from the lower respiratory tract specimens or blood samples after admission [@b0070].

2.4. Chest CT protocol and evaluation {#s0030}
-------------------------------------

Chest CT scans were obtained using either of the following CT scanners: SOMATOM Definition AS+, SOMATOM Spirit, or SOMATOM Perspective (Siemens Healthineers, Forchheim, Germany). The parameters used for the scanning protocol were as described in our previous study [@b0080]. All initial CT images were assessed by three radiologists (Heshui Shi, Jin Gu and Yanqing Fan) with more than 15 years of experience in thoracic radiology. The predominant three CT findings included ground glass opacity (GGO), crazy-paving pattern and consolidation, and any other CT characteristics were described on the basis of previous studies on COVID-19 patients [@b0080], [@b0085]. The extent of pulmonary involvement of all of these abnormalities in each lung lobe was evaluated using a semi-quantitative scoring system [@b0090]. CT score for each of the three findings at each of the 5 lung lobes was scored from 0 to 5, with a total score of 0--25. Each lobe was scored as follows: 0, no involvement; 1, ≤5% involvement; 2, 6--25% involvement; 3, 26--49% involvement; 4, 50--75% involvement; 5, \>75% involvement.

2.5. Statistical analysis {#s0035}
-------------------------

The Kolmogorov--Smirnov test was used to check the normality. Data were expressed as the mean ± SD, median (IQR) and n (%) for normally, non-normally continuous variables and categorical variables, respectively. Differences between two groups stratified by FBG were assessed using independent-sample Student's *t* test, Mann-Whitney test, *χ^2^* test, or Fisher's exact test, as appropriate. Univariate and multivariate logistic regression models were used to explore the risk factors associated with in-hospital death and complications. A two-sided p value \<0.05 was considered statistically significant. Analyses were performed using SPSS software version 21 (IBM, Chicago, IL, USA).

3. Results {#s0040}
==========

3.1. Demographics and clinical characteristics {#s0045}
----------------------------------------------

From Dec 31, 2019, to Apr 5, 2020, a total of 154 consecutive confirmed COVID-19 patients with diabetes were admitted to hospital. Of these, 12 were excluded due to the lack of serum glucose test results and 10 were excluded because of missing CT images or other key information in their medical records. Thus, 132 patients (85 from Wuhan Union hospital of Tongji Medical College and 47 from Jinyintan Hospital) were eventually included in this study.

The baseline clinical characteristics of all patients and the subgroups (stratified by the levels of FBG) are presented in [Table 1](#t0005){ref-type="table"} . For the study cohort, the median age was 65 years (IQR, 57--71) and 70 (53%) patients were male. 130 patients (98.5%) were type 2 diabetes and the median disease duration was 8.5 years (IQR, 4--11.75). The most common symptoms at onset were fever (107, 81.1%) and cough (87, 65.9%), followed by shortness of breath (42.4%) and sputum (35.6%). The median time from onset of symptoms to hospital admission was 10 days (IQR, 7.0--16.0). More than half of the patients had at least one other comorbidity, with hypertension being the most common (64.4%), followed by cardiovascular (13.6%) and cerebrovascular diseases (9.1%). Among 132 patients, 39 (29.3%) patients received high flow nasal cannula oxygen therapy, 10 (7.6%) patients needed noninvasive respiratory support and 5 (3.8%) patients required endotracheal intubation. In addition, most of the patients received antiviral (99.2%) and antibiotic treatments (85.6%), and some patients have taken corticosteroids (29.5%), intravenous immunoglobulin (22.7%) and antifungal agents (11.4%).Table 1Demographics, and baseline clinical characteristics of COVID-19 patients with diabetes.All patients (n = 132)Group 1 (n = 76)Group 2 (n = 56)*p* valueAge, years65(57--71)65(58--71)65(56--71)0.841 ≥6571(53.8)42(55.3)29(51.8)0.692 \<6561(46.2)34(44.7)27(48.2)--  Sex Male70(53)44(57.9)26(46.4)0.192 Female62(47)32(42.1)30(53.6)--  Diabetes Type Type 2 diabetes130(98.5)75(98.7)55(98.2)1.000 Type 1 diabetes2(1.5)1(1.3)1(1.8)--Diabetes duration, year8.5(4--11.75)6(2--11)10(5--12)0.033  Exposure Exposure to Huanan seafood market10(7.6)6(7.9)4(7.1)1.000 Exposure to patients[\*](#tblfn1){ref-type="table-fn"}20(15.2)14(18.4)6(10.7)0.222  Other comorbidities Any88(66.7)48(63.2)40(71.4)0.319 Hypertension85(64.4)46(60.5)39(69.6)0.324 Cardiovascular disease18(13.6)14(18.4)4(7.1)0.062 Cerebrovascular disease12(9.1)6(7.9)6(10.7)0.578 Chronic pulmonary disease6(4.5)2(2.6)4(7.1)0.401 Chronic kidney disease4(3)3(3.9)1(1.8)0.637 Chronic liver disease4(3)1(1.3)3(5.4)0.311 Malignancy3(2.3)1(1.3)2(3.6)0.574  Signs and symptoms Fever107(81.1)57(75)50(89.3)0.038 Maximum temperature, °C38(37.43--38.8)38(36.8--38.8)38(37.5--38.8)0.331  ≤37.332(24.2)23(30.3)9(16.1)0.060  37.3--3842(31.8)20(26.3)22(39.3)0.114  38.1--3946(34.8)28(36.8)18(32.1)0.476  ≥39.112(9.1)5(6.6)7(12.5)0.242 Cough87(65.9)46(60.5)41(73.2)0.154 Shortness of breath56(42.4)28(36.8)28(50)0.166 Sputum47(35.6)21(27.6)26(46.4)0.026 Fatigue44(33.3)22(28.9)22(39.3)0.213 Chest tightness16(12.1)8(10.5)8(14.3)0.513 Dyspnea14(10.6)6(7.9)8(14.3)0.239 Myalgia9(6.8)3(3.9)6(10.7)0.240 Diarrhea9(6.8)7(9.202(3.6)0.357 Pharyngalgia5(3.8)3(3.9)2(3.6)1.000 Dizziness4(3.0)2(2.6)2(3.6)1.000 Nausea3(2.3)3(3.9)0(0)0.262 Abdominal pain2(1.5)2(2.6)0(0)0.508 Vomiting0(0)0(0)0(0)--Heart rate, bpm89(80--98)88(80--98)90(81--100)0.305Respiratory rate21(20--43)21(20--23)22(20--24)0.570Systolic blood pressure, mmHg80(74--87)80(74--87)80(73--87)0.906Diastolic blood pressure, mmHg130.1 ± 15.72128.5 ± 15.48132.27 ± 15.910.174Oxygen saturation (%)95(90--97)97(92--98)93(88--96)0.004  Treatment High flow nasal cannula oxygen39(29.3)20(26.3)19(33.9)0.343   Mechanical ventilation  Non-invasive10(7.6)5(6.6)5(8.9)0.864  Invasive5(3.8)2(2.6)3(5.4)0.650 Antiviral treatment131(99.2)64(84.2)49(87.5)0.423 Antibiotic treatment113(85.6)65(85.5)52(92.9)0.190 Glucocorticoids39(29.5)17(22.4)22(39.3)0.053 Intravenous immunoglobulin therapy30(22.7)16(21.1)14(25)0.593 Antifungal therapy15(11.4)7(9.2)8(14.3)0.364  Duration from onset of symptoms to, median (IQR), days Hospital admission10(7--16)11(7--18)10(7--15)0.469 ARDS14(9--23)18(9--24)14(8--220)0.736 ICU15(10--21)18(11--24)12(10--19.75)0.213 Death21(16--28)24.5 (14.25--40.75)21(16--22)0.639 Discharge33(24--49)32.5 (22.5--48.5)33(25--50)0.847  Complications Any31(23.5)11(14.5)20(35.7)0.004 ARDS20(15.2)7(9.2)13(23.2)0.027 Acute cardiac injury8(6.1)1(1.3)7(12.5)0.010 Secondary infection8(6.1)4(5.3)4(7.1)0.722 Acute renal injury2(1.5)1(1.3)1(1.8)1.000  Clinical outcomes ICU Admission19(14.4)7(9.2)12(21.4)0.048 Death15(11.4)4(5.3)11(19.6)0.010[^2][^3][^4]

Compared with group1, patients in group 2 were more likely in need of systematic corticosteroid treatment, and had more fever, more sputum, longer disease duration and lower oxygen saturation, but had no significant differences in age, gender and some other characteristics ([Table 1](#t0005){ref-type="table"}).

3.2. Laboratory findings {#s0050}
------------------------

On admission-laboratory test results of all ﻿patients and the subgroups are presented in [Table 2](#t0010){ref-type="table"} . In all patients, there were abnormal routine blood indices, including, among others, decreased absolute lymphocyte count (76, 57.6%) and increased platelet count (63, 47.7%), and abnormal coagulation profile including increased d-dimer (62, 47%) and fibrinogen (55, 41.7%). Some patients had an abnormal liver function, including increased alanine aminotransferase (ALT; 35, 26.5%) and aspartate aminotransferase (AST; 36, 27.3%). Some patients had abnormal myocardial enzymes, including elevated lactate dehydrogenase (LDH; 62, 47%),high-sensitivity troponin I (22, 16.7%) and decreased creatine kinase (33, 25%). Regarding the inflammation-related biomarkers, more than half of the patients had an increased serum ferritin (87, 65.9%), interleukin-6 (IL-6; 71, 53.8%), erythrocyte sedimentation rate (ESR; 98, 74.2%), C-reactive protein (CRP; 94, 71.2%) and serum amyloid protein A levels (SAA; 85, 64.4%).Table 2Laboratory findings of COVID-19 patients with diabetes.Normal rangeAll patients (n = 132)Group 1 (n = 76)Group 2 (n = 56)*p* value  Routine blood test White blood cell count, ×10^9^/L3.5--9.55.60(4.06--8.14)5.51(4.03--7.29)6.11(4.11--9.61)0.225  Increased--21(15.9)8(10.5)13(23.2)0.050  Decreased--16(12.1)10(13.2)6(10.7)0.649 Neutrophil count, ×10^9^/L1.8--6.34.44(2.65--8.15)4.00(2.63--7.23)6.76(2.85--9.62)0.151 Lymphocyte count, ×10^9^/L1.1--3.20.83(0.64--1.11)1.05(0.69--1.32)0.73(0.58--0.97)0.007  Decreased--76(57.6)37(48.7)39(69.6)0.017 Platelet count, ×10^9^/L125--350204(136--303)200(141.5--283.5)204.5(124--334.75)0.796  Increased--63(47.7)37(48.7)26(46.4)0.276  Decreased--24(18.2)9(11.8)15(26.8)0.056 Haemoglobin, g/L130--175116.93 ± 17.73116.19 ± 18.23117.96 ± 17.170.608  Decreased--85(64.4)48(63.2)37(66.1)0.502  Coagulation profile D-dimer, µg/L\<0.51.61(0.56--3.04)1.51(0.35--2.57)1.72(0.72--3.39)0.039 Increase_62(47)29(38.2)33(58.9)0.117 Prothrombin time, s11--1611.4(10.1--12.78)11.2(10.10--12.60)11.55(10.03--14.48)0.438 Activated partial thromboplastin time, s28.0--43.527.85(23.98--33.88)29.30(25.15--36.35)26.40(21.85--31.60)0.137 Fibrinogen, g/L2.0--4.04.84(3.98--6.60)4.88(3.95--6.19)4.70(4.05--7.40)0.490 Increased_55(41.7)30(39.5)25(44.6)0.908  Blood biochemistry Glucose, mmol/L3.9--6.19.35(7.1--13.8)7.34(6.30--8.80)14.79(12.56--17.88)\<0.001 Glycosylated hemoglobin, %4.0--6.07.65(6.93--8.88)7.05(6.20--7.60)8.80(7.63--9.38)\<0.001 Albumin, g/L35--5532.55(29.1--36.03)31.9(30.2--36.78)31.35(27.90--34.18)0.077  Decreased--84(63.6)43(56.6)41(73.2)0.103 Alanine aminotransferase, U/L5--5032.4 (15.75--56.25)31(14--56)37(17--61)0.359  Increased--35(26.5)19(25)16(28.6)0.957 Aspartate aminotransferase, U/L15--4035 (20.5--47.1)35(18--49)34.5 (22.03--47.15)0.560  Increased--36(27.3)24(31.6)12(21.4)0.107 Serum creatinine, μmol/L57--11166.5 (54.35--91.7)72.6 (53.8--95.0)64.9(55.2--87.48)0.437 Creatine kinase, U/L50--31043(30--110)51(26--110)41.5(32--142.4)0.896  Increased--5(3.8)3(3.9)2(3.6)1.000  Decreased--33(25)19(25)14(25)0.306 Lactate dehydrogenase, U/L109--245327.04 ± 140.32307.41 ± 142.18350.11 ± 136.510.159  Increased--62(47)30(39.5)32(57.1)0.061 Myoglobin, ng/mL\<146.959.8(30.75--134.3)65.75(35.78--144.18)54.6(27.7--116.5)0.511 High-sensitivity troponin I, pg/mL\<26.29.35(3.58--32.03)9.2(3.38--31.88)9.55(3.75--37.4)0.646 Increased_22(16.7)9(11.8)13(23,2)0.242  Infection-related biomarkers Serum ferritin, ng/mL21--274.7566.78(363.76--945.4)538.95(356.64--926.37)642.16(371.31--1082.91)0.567  Increased--87(65.9)52(68.4)35(62.5)0.748 Interleukin-6, pg/mL\<79.97(7.4--13.07)8.64(6.74--12.25)10.77(8.05--15.5)0.032  Increased--71(53.8)34(44.7)37(66.1)0.006 Procalcitonin, ng/mL\<0.50.05(0.05--0.11)0.05(0.05--0.13)0.05(0.05--0.09)0.940 Erythrocyte sedimentation rate, mm/h\<1553.63 ± 27.5349.28 ± 27.5961.61 ± 25.930.025  Increased--98(74.2)63(82.9)35(62.5)0.655 C-reactive protein, mg/L\<847.45(13.23--108.8)33.29(5.35--97.75)66.59(27.5--128.8)0.008  Increased--94(71.2)50(65.8)44(78.6)0.004 Serum amyloid protein A, mg/L\<10176.5(60.68--245.76)170.7(41.45--248.35)185(75.2--240.7)0.713  Increased--85(64.4)48(63.2)39(69.6)0.695[^5]

Compared with group 1, patients in group 2 had lower absolute lymphocyte count (0.73 \[IQR, 0.58--0.97\] vs. 1.05 \[IQR, 0.69--1.32\]; *p* = 0.007), and higher d-dimer (1.72 \[IQR, 0.72--3.39\] vs. 1.51 \[IQR, 0.35--2.57\]; *p* = 0.039), IL-6 (10.77 \[IQR, 8.05--15.50\] vs. 8.64 \[IQR, 6.74--12.25\]; *p* = 0.032), ESR (61.61 ± 25.93 vs. 49.28 ± 27.59; *p* = 0.025) and CRP (66.59 \[IQR, 27.50--128.80\] vs. 33.29 \[ IQR, 5.35--97.75\]; *p* = 0.004) ([Table 2](#t0010){ref-type="table"}).

3.3. The initial HRCT score and features {#s0055}
----------------------------------------

All patients had abnormal CT imaging features as presented in [Table 3](#t0015){ref-type="table"} . 119 (90.2%) patients had bilateral lung involvement; 70 (53%) patients showed both central and peripheral distribution, and 87 (65.9%) patients showed diffuse involvement ([Fig. 1](#f0005){ref-type="fig"} , A-C). The most frequent CT characteristics were ground glass opacity (GGO; 80, 60.6%) ([Fig. 1](#f0005){ref-type="fig"}, D,E), air bronchogram (95, 72%), interlobular septal thickening (84, 63.9%) and crazy-paving pattern (39, 29.5%), followed by pleural effusion (23，17.4%) and bronchiolar dilatation (21, 15.9%). Other less common features on CT included round cystic changes, pericardial effusion and lymphadenopathy. Tree-in-bud signs and cavitation were not observed in any of the patients.Table 3The initial HRCT score and features of COVID-19 patients with diabetes.HRCT scoreAll patients (n = 132)Group 1 (n = 76)Group 2 (n = 56)*p* value Left upper lobe2(1--3)2(1--3)3(1--4)0.020 Left lower lobe3(1--4)2(1--4)3(2--5)0.238 Right upper lobe2(1--4)2(1--3)3(1--4)0.017 Right middle lobe2(3--1)1(0--3)2(1--4)0.063 Right lower lobe3(2--5)3(1--5)3(2--5)0.040 Total CT score of the pulmonary involvement11.5(6--18)9.5(5--17)14.5(9--20)0.010  HRCT characteristicsLung involvement Unilateral13(9.8)8(10.5)5(8.9)0.761 Bilateral119(90.2)68(89.5)51(91.1)--  Location Central7(5.3)5(6.6)2(3.6)0.698 Peripheral55(41.7)32(42.1)23(41.1)0.905 Both central and peripheral70(53)39(51.3)31(55.4)0.646  Predominant distribution Septal/subpleural62(47)34(44.7)28(50)0.549 Peribronchovascular15(11.4)10(13.2)5(8.9)0.449 Both2(1.5)1(1.3)1(1.8)1.000 Random52(39.4)31(40.8)21(37.5)0.702 Bilateral lower lobe1(0.8)0(0)1(1.8)0.424  Extent of lesion involvement Focal7(5.3)4(5.3)3(5.4)0.981 Multifocal38(28.8)27(35.5)11(19.6)0.046 Diffuse87(65.9)45(59.2)42(75)0.059  Predominant CT pattern Ground glass opacity80(60.6)48(63.2)32(57.1)0.485 Consolidation29(22.0)15(19.7)14(25.0)0.470 Reticular pattern5(3.8)2(2.6)3(5.4)0.650 Mixed pattern18(13.6)11(14.5)7(12.5)0.744Air bronchogram95(72)50(65.8)45(80.4)0.066Interlobular septal thickening84(63.9)48(63.2)36(64.3)0.894Crazy paving39(29.5)23(30.3)16(28.6)0.833Bronchiolar dilatation21(15.9)14(18.4)7(12.5)0.358Round cystic changes11(8.3)4(5.3)7(12.5)0.243Tree-in-bud0(0)0(0)0(0)--Cavitation0(0)0(0)0(0)--Pleural effusion23(17.4)14(18.4)9(16.1)0.770 Unilateral11(8.3)9(11.8)2(3.6)0.167 Bilateral12(9.1)5(6.6)7(12.5)0.242Pericardial effusion13(9.8)8(10.5)5(8.9)0.761Lymphadenopathy2(1.5)1(1.3)1(1.3)1.000[^6]Fig. 1The initial HRCT score and features. (A--C) Transverse CT scans in a 59-year-old female with type 2 diabetes for 10 years. FBG was 20.7 mmol/L on admission. (A) Scan obtained on the 7th day from onset of symptoms shows extensive ground-glass opacities in both lungs. (B, C) Scan obtained on the 13th and 20th day shows progressive expansion of the bilateral pulmonary lesions and development of consolidations. The patient died 13 days after the final scan. (D, E) Transverse CT scans in a 68-year-old female with type 2 diabetes for 3 years. FBG was 8.8 mmol/L on admission. (D) Scan obtained on the 6th day from onset of symptoms shows focal patchy ground glass opacities in the left upper lobe posteriorly. (E) Scan obtained on the 12th day shows that the previous ground-glass opacities were nearly resolved. The patient was discharged from hospital 3 days after the final scan. (F) Comparison of the total HRCT score in two groups with different fasting blood glucose (FBG) levels.

According to the semi-quantitative scoring system, the median total CT score of the pulmonary involvement was 11.5 (IQR, 6--18). Compared with group 1, patients in group 2 had higher total CT score (14.5 \[IQR, 9--20\] vs. 9.5 \[IQR, 5--17\]; *p* = 0.010) ([Fig. 1](#f0005){ref-type="fig"}, F). CT score of the bilateral upper lobes and right lower lobe in group 2 patients were also greater than patients in group 1. There were no significant differences in baseline CT characteristics mentioned above.

3.4. Clinical complications and outcomes {#s0060}
----------------------------------------

Among 132 patients, there were 31 patients (23.5%) with at least one complication; 20 (15.2%) patients developed ARDS, 8 (6.1%) patients had acute cardiac injury, 8 (6.1%) patients had secondary infection, and 2 (1.5%) patients with acute renal injury. The median time from onset of symptoms to ARDS was 14 days (IQR, 9--23). For the primary outcome, 19 (14.4%) patients were admitted to ICU, and 15 (11.4%) patients died. The median time from onset of symptoms to ICU admission was 15 days (IQR, 10--21), whereas the median duration to death and discharge was 21 days (IQR, 16--28) and 33 days (IQR, 24--49), respectively ([Table 1](#t0005){ref-type="table"}).

Compared with group 1, patients in group 2 had a higher death rate (19.6% vs. 5.3%, *p* = 0.010), were more likely to require ICU care (21.4% vs. 9.2%, *p* = 0.048) and to have more in-hospital complications, including ARDS (23.2% vs. 9.2, *p* = 0.027) and acute cardiac injury (12.5% vs. 1.3%, *p* = 0.010).

3.5. Prognostic factors {#s0065}
-----------------------

The risk factors associated with in-hospital death and complications are shown in [Supplemental Table S1](#s0090){ref-type="sec"}. According to univariable analysis, the admission glucose, absolute lymphocyte count and d-dimer were associated with an increased risk of in-hospital death and complications. Total CT score of the pulmonary involvement, white blood cell count, albumin, LDH, myoglobin, high-sensitivity troponin I and procalcitonin were also associated with odds of in-hospital complications.

Considering the relatively small number of in-hospital deaths (n = 15) and complications (n = 31) in our study and to avoid overfitting of the model, we have chosen age, hypertension, total CT score of the pulmonary involvement, lymphocyte count and six ﻿laboratory indices as indicators for the relative different organ functions in the final multivariable analysis using a stepwise algorithm model. Those six laboratory indices included FBG, d-dimer, ALT, LDH, creatinine and CRP. In the multivariable analysis, compared with admission glucose of ≤11 mmol/l, patients with a blood glucose of \>11 mmol/l had an increased risk of death (OR: 7.629, 95%CI: 1.391--37.984) and in-hospital complications (OR: 3.232, 95%CI: 1.393--7.498). D-dimer ≥1.5 μg/mL (OR: 6.645, 95%CI: 1.212--36.444) and total CT score ≥10 (OR: 7.792, 95%CI: 2.195--28.958) were also associated with increased odds of death and in-hospital complications, respectively ([Fig. 2](#f0010){ref-type="fig"} ).Fig. 2The risk factors associated with in-hospital death (A) and complications (B) on multivariable logistic regression analysis.

4. Discussion {#s0070}
=============

The median age of COVID-19 patients with diabetes were (65 \[IQR: 57--71\] years) in our study, higher than previous publications on patients without diabetes (53 \[IQR: 40--63\] years) [@b0095] and the overall COVID-19 population (47 \[IQR: 35--58\] years) [@b0100]. Fever and cough were the most common symptom, which were consistent with previous reports [@b0005], [@b0015]. A recent multi-centered study showed that patients with FBG \> 10 mmol/L had multiple organ injury and a higher mortality rate than individuals with FBG levels from 3.9 to 10 mmol/L [@b0095]. Similarly, in our study, patients with poorly-controlled FBG (\>11 mmol/L) had a greater incidence of acute cardiac injury, ARDS, and ICU entry, and a higher death rate than those with FBG ≤ 11 mmol/L.

Additionally, a previous study reported that the plasma glucose level was an independent predictor for morbidity and mortality in SARS [@b0040]. The present study showed that FBG of \>11 mmol/l was associated with an increased risk of death and complications in COVID-19 patients with diabetes. Similarly, a large cohort study by Kornum et al. [@b0105] found that the admission FBG of \>11 mmol/L was a predictor for mortality in type 2 diabetic patients with community-acquired pneumonia (CAP). It was proposed that hyperglycemia may impair the normal endothelial function, hinder phagocytosis, delay the chemotaxis and reduce the microbiocidal capacity [@b0110], [@b0115], [@b0120]. These abnormalities are prone to progress when the glucose level is greater than 11 mmol/L and can be improved by better glycemic control [@b0110], [@b0115], [@b0120]. A recent publication on COVID-19 patients showed that although glucose level was higher on admission, it subsequently decreased, while it continued to increase in deceased patients [@b0125]. Therefore, timely blood glucose testing and better glycemic control play a key role in COVID-19 patients' prognosis.

As described in recent studies [@b0005], [@b0130], [@b0135], [@b0140], coagulation abnormalities were common in severe COVID-19 patients, and were marked by elevated d-dimer concentrations. In our study, d-dimer of ≥1.5 μg/mL was associated with higher odds of death, similar to a previous report in 191 COVID-19 patients [@b0140]. The state of hypoxia in severe pneumonia can lead to a hypercoagulable state of the blood by activating the exogenous coagulation pathway, and can also stimulate thrombus formation by increasing the blood viscosity [@b0145]. In addition, chronic hyperglycemia can cause vascular injury, oxidative stress and inflammation, which can lead to the formation of atherosclerosis and thrombus [@b0150]. Therefore, severe ﻿SARS-CoV-2 infection with diabetes is more likely to cause coagulopathy and resultant poor outcome.

The present study found that the HRCT score of ≥10 was associated with increased odds of in-hospital complications. CT was an important inspection tool for COVID-19 and the score of the lesions involvement of the lung was correlated with histopathology [@b0155]. In our study, patients with FBG of \>11 mmol/L had a significantly higher CT score than those with FBG of ≤11 mmol/L. This might be explained by the previous finding that patients with diabetes and hyperglycemia have restrictive ventilatory dysfunction, as well as small airway obstruction and diffuse dysfunction [@b0160]. It was suggested that the CT score may be used as one of the indicators for poor prognosis in COVID-19 patients with diabetes, but large-scale multicenter studies are needed to further confirm this finding. Additionally, in our study, a considerable proportion of patients had pleural effusion (17.4%), higher than previously reported (2.5% & 5.0%) [@b0080], [@b0085]. Some previous studies have shown that pleural effusion is an independent predictor for mortality in patients with CAP and MERS [@b0165], [@b0170]. Thus, the early appearance of pleural effusion in COVID-19 patients with diabetes should be paid more clinical attention.

The present study has several limitations. First, this was a retrospective study, and the findings might be limited by the small sample size. Second, some laboratory results were missing in the electronic medical records, which may have led to a selection bias when identifying the risk factors for adverse outcomes. Third, this study did not assess the non-diabetic patients, since there have been numerous descriptive studies on the clinical and imaging characteristics of the general population.

In conclusion, our study suggested that COVID-19 patients with poorly-controlled FBG (\>11 mmol/L) had worse outcomes. Admission FBG of \>11 mmol/L was a risk factor for death and complications in COVID-19 patients with diabetes. Elevated d-dimer and HRCT score also contributed to the adverse outcomes. Our findings may provide useful information for the management of this special population and guide the strategies for more targeted intervention to improve the prognosis.
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